Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Doctors create new tool to predict surgery difficulty for rare tumors

NCT ID NCT07412158

Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study created a new imaging-based grading system to help doctors predict how complex and risky surgery will be for patients with rare adrenal and nerve tumors called PPGL. Researchers used 3D scans from 500 patients to develop the system, aiming to improve surgical planning and safety. The study did not test a treatment but focused on better understanding and measuring surgical risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Jan 2017

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who underwent surgical resection and were definitively diagnosed with pheochromocytoma or paraganglioma (PPGL) by postoperative pathology at Peking University First Hospital between January 1, 2017 and December 31, 2025 were included in this study.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ① Patients who underwent curative surgical resection (including laparoscopic, robot-assisted, or open surgery) at our hospital within the study period; * Postoperative pathological confirmation of PPGL; * Availability of complete preoperative imaging data; ④ Availability of complete perioperative clinical data, including anesthesia records, surgical records, and postoperative hospitalization information; ⑤ Age ≥ 18 years. Exclusion Criteria: * ① Lack of key imaging data or poor image quality that could not meet evaluation requirements; * Requirement for concurrent complex surgery for other diseases, making it difficult to independently assess perioperative indicators; ③ History of biopsy only, exploratory surgery, or presence of recurrence, bilateral, or multifocal lesions, preventing independent evaluation; ④ Primary tumors located in special sites (e.g., pelvic, bladder, spermatic cord, or other rare extra-adrenal locations), leading to incomparable surgical approaches and perioperative outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pheochromocytoma and paraganglioma (PPGL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

paraganglioma pheochromocytoma pheochromocytoma-paraganglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pheochromocytoma and paraganglioma (PPGL) Quantitative assessment Risk grading system

Contacts and locations

Locations

  • Department of Urology, Peking University First Hospital, Beijing, 100034

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.